MedTrace Logo

Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors

NCT05150457 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2022-09-27

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and tolerability of BNA035 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy for each combination regimen.

Conditions

  • Refractory Solid Tumors

Interventions

DRUG

BNA035

Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody

Sponsors & Collaborators

  • Binacea Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Josh Xiao, PhD · Binacea Pharma, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-08
Primary Completion
2023-11-30
Completion
2025-11-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05150457 on ClinicalTrials.gov